AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook Post Contentazn, azncfRead More You might also be interested in reading Vidrala reports FY results. July 29, 2025 In Mainstream ← Previous post Next post →